BCDA Key Statistics, Chart & Performance
The current stock price of BCDA is 1.32 USD. In the past month the price decreased by -8.39%. In the past year, price decreased by -38.39%.
BCDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.78B |
Related stock screener links
About BCDA
Company Profile
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Company Info
BIOCARDIA INC
320 Soquel Way
Sunnyvale CALIFORNIA 94070 US
CEO: Peter Altman
Employees: 17
Phone: 16502260123
BIOCARDIA INC / BCDA FAQ
Can you describe the business of BIOCARDIA INC?
BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Can you provide the latest stock price for BIOCARDIA INC?
The current stock price of BCDA is 1.32 USD. The price increased by 0.76% in the last trading session.
What is the dividend status of BIOCARDIA INC?
BCDA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCDA stock?
BCDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for BIOCARDIA INC?
BIOCARDIA INC (BCDA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for BCDA stock?
BIOCARDIA INC (BCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.48).
Should I buy BCDA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BCDA.
BCDA Technical Analysis
BCDA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCDA. BCDA has a bad profitability rating. Also its financial health evaluation is rather negative.
BCDA Financial Highlights
Over the last trailing twelve months BCDA reported a non-GAAP Earnings per Share(EPS) of -1.48. The EPS increased by 17.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -421.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCDA Forecast & Estimates
8 analysts have analysed BCDA and the average price target is 15.81 USD. This implies a price increase of 1097.73% is expected in the next year compared to the current price of 1.32.
For the next year, analysts expect an EPS growth of 61.55% and a revenue growth -84.28% for BCDA